This broad approach, called in vivo cell therapy, has the potential to offer the best of both worlds, with scalability and lower cost, not to mention a better safety profile, while maintaining the ...
An investigator-initiated trial examining YolTech Therapeutics’ in vivo gene editing-based ‘life-long cure’ for patients living with a rare genetic disorder has seen the treatment able to ...
Zacks Investment Research on MSN7d
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New IndicationIntellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...
Shareholder nervousness likely stems from concern that the lacklustre efficacy may translate to other Editas programmes, including EDIT-103, an in vivo therapy which targets the eye disease ...
AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...
Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...
Whether your in vivo therapy is being delivered by adeno-associated viruses or other viruses, lipid nanoparticles or virus-like particles, or it’s an autologous or allogeneic ex vivo gene therapy, all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback